Ocugen, Inc. (OCGN)
0.8137
-0.03
(-3.27%)
USD |
NASDAQ |
Oct 15, 16:00
0.8136
0.00 (0.00%)
After-Hours: 20:00
Ocugen Cash from Operations (TTM) : -60.87M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -60.87M |
| March 31, 2026 | -59.40M |
| December 31, 2025 | -56.96M |
| September 30, 2025 | -53.37M |
| June 30, 2025 | -51.72M |
| March 31, 2025 | -50.90M |
| December 31, 2024 | -42.14M |
| September 30, 2024 | -43.08M |
| June 30, 2024 | -45.51M |
| March 31, 2024 | -54.41M |
| December 31, 2023 | -62.05M |
| September 30, 2023 | -67.67M |
| June 30, 2023 | -68.26M |
| March 31, 2023 | -63.25M |
| December 31, 2022 | -60.08M |
| September 30, 2022 | -55.97M |
| June 30, 2022 | -49.72M |
| March 31, 2022 | -57.72M |
| December 31, 2021 | -47.94M |
| September 30, 2021 | -39.42M |
| June 30, 2021 | -34.02M |
| March 31, 2021 | -15.31M |
| December 31, 2020 | -14.71M |
| September 30, 2020 | -19.17M |
| June 30, 2020 | -18.64M |
| Date | Value |
|---|---|
| March 31, 2020 | -18.91M |
| December 31, 2019 | -16.89M |
| September 30, 2019 | -10.94M |
| June 30, 2019 | -15.73M |
| March 31, 2019 | -17.58M |
| December 31, 2018 | -11.63M |
| September 30, 2018 | -13.16M |
| June 30, 2018 | -11.97M |
| March 31, 2018 | -12.39M |
| December 31, 2017 | -23.02M |
| September 30, 2017 | -24.59M |
| June 30, 2017 | -24.33M |
| March 31, 2017 | -25.24M |
| December 31, 2016 | -25.74M |
| September 30, 2016 | -26.84M |
| June 30, 2016 | -28.26M |
| March 31, 2016 | -29.19M |
| December 31, 2015 | -30.03M |
| September 30, 2015 | -28.18M |
| June 30, 2015 | -24.10M |
| March 31, 2015 | -22.08M |
| December 31, 2014 | -18.40M |
| September 30, 2014 | -18.45M |
| June 30, 2014 | -19.32M |
| March 31, 2014 | -17.54M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Anika Therapeutics, Inc. | 5.977M |
| Gilead Sciences, Inc. | 13.55B |
| MannKind Corp. | -8.217M |
| Nektar Therapeutics | -233.79M |